Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Treatment for Stroke in Mice Reduces Brain Damage, Promotes Motor Recovery

By RIKEN | May 16, 2019

Brain injuries like stroke can be debilitating and require time-sensitive treatment. Clotting factors like thrombin are commonly administered to patients, but there are many other stroke-related signs that can be targeted, such as swelling and ion imbalances in the surrounding fluids. New research shows that brain fluids can be normalized with adrenergic receptor antagonists, a combination of drugs to block the activity of (nor)adrenaline in the brain. This experimental treatment for stroke aided motor recovery and reduced cell death in mice, as reported in the Proceedings of the National Academy of Sciences om May 13.

A major consequence of stroke is an immediate imbalance in the ion concentrations of fluids that bathe brain cells. Potassium levels spike and fluid accumulates, which leads to swelling, a major cause of stroke injury. “We know that the water dynamics in the brain immediately during and after a stroke are critical, so we focused on the pathways that move fluids in and out of cells,” explains lead author Hiromu Monai of the RIKEN Center for Brain Science and Ochanomizu University. One way to lower potassium and get neurons active again is by administering adrenergic receptor (AdR) antagonists, drugs that counteract the electrical and chemical disturbance that accompanies a stroke. These antagonist drugs have been found to promote fluid exchange in normal brains by another of this study’s co-authors, Maiken Nedergaard of the University of Rochester Medical Center.

A cocktail of AdR blockers was successful in reducing both the area of tissue damage and potassium levels in stroked mice. Moreover, even one or two hours post-stroke, administration of AdR blockers was effective in stopping the infarct from spreading. Mice were also able to recover the use of their forepaw much more quickly when treated with AdR blockers. The researchers found that levels of a water channel called aquaporin 4 were lower following a stroke.

“We think that preserving aquaporin levels is critical to protecting brain tissue during stroke,” says Monai.

To test this idea, they used genetically engineered mice that lacked the aquaporin 4 water channel. These mice did not benefit from AdR blocker treatment and their brain potassium levels remained high after stroke, supporting the idea that the neuroprotective effect occurs through the action of aquaporin 4 water channels.

“Keeping potassium levels in balance is an alternative therapeutic strategy for stroke, and we found that adrenergic receptor blockers promote this normalization,” says Monai. “Recovering motor function following a stroke is so important, and we also saw improvements in the mice treated with AdR blockers.”


Filed Under: Neurological Disease

 

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE